Medtronic, Bos Sci ordered to pay J&J about $1.2B for stent patents

The U.S. District Court in Delaware has awarded Johnson & Johnson (J&J) damages totaling $406.7 million and pre-judgment interest totaling $296 million from Boston Scientific and $521 million from Medtronic, in a case involving a stent patent owned by J&J.

Boston Scientific said it will appeal the judgment.

On Sept. 15, the U.S. Delaware District Court Judge Sue Robinson Monday granted J&J’s subsidiary, Cordis, a motion for final judgment against Boston Scientific and Medtronic, in their cases involving Cordis’ Palmaz balloon expandable stent patent.

The case relates to GFX and Microstent II from the Minneapolis-based Medtronic and the NIR stent from the Natick, Mass.-based Boston Scientific.

The original suit was filed in 1997, and Boston Scientific said it has not sold the NIR stent since 2004.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.